Nasopharyngeal Carcinoma Clinical Trials

• Patients with nasopharyngeal carcinoma who have recurred/metastasized after initial treatment or radical treatment;

• Age 18-75, male or female;

• Pathological diagnosis of nasopharyngeal carcinoma;

• ECOG score 0-1;

• Have not previously received any anti-tumor therapy such as radiotherapy, chemotherapy, immunotherapy or biotherapy for recurrence/metastasis;

• No contraindications of chemotherapy, immunotherapy and targeted therapy;

• At least 1 measurable lesion that meets RECIST 1.1 criteria;

• Blood routine examination standards should meet: WBC≥3.0×109/L, ANC≥1.5×109/L, PLT≥100×109/L, HGB≥90g/L (no blood transfusion and blood products within 14 days, no G-CSF and other hematopoietic stimulating factors are used to correct);

• Biochemical tests should meet the following criteria: TBIL≤2.0×ULN, ALT, AST≤2.5×ULN, BUN and CRE≤1.5×ULN or endogenous creatinine clearance ≥60ml/min (Cockcroft-Gault formula);

• Good coagulation function: defined as International standardized ratio (INR) or prothrombin time (PT) ≤1.5 times ULN; If the subject is receiving anticoagulant therapy, as long as PT is within the intended range of anticoagulant drug use;

• The myocardial enzyme spectra were in the normal range;

• Women of childbearing age must already be using reliable contraception or have had a pregnancy test (serum or urine) within 7 days of enrollment with a negative result and be willing to use an effective method of contraception during the trial and for 3 months after the last anti-PD-1 antibody administration. For male subjects whose partners are women of reproductive age, effective contraception should be used during the trial and within 3 months after the last anti-PD-1 antibody administration;

• The subjects voluntarily joined the study, signed informed consent, had good compliance, and cooperated with follow-up;